Drug Database
PI

piperacillin (piperacillin, KRKA / Isipen)

✓ Approved

Krka · Small Molecule · Small Molecule

What is piperacillin?

piperacillin is a small molecule developed by Krka. It is approved for therapeutic indications via unknown.

Drug Profile

Brand Namespiperacillin, KRKA, Isipen
CompanyKrka
Drug ClassSmall Molecule
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Krka

Therapeutic Indications

piperacillin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsSalmonellosis✓ Approved

Related Research Articles

PubMedJapanese journal of infectious diseases2026-08-30

Superior in vitro Activity of Cefepime-Enmetazobactam Over Ceftazidime-Avibactam and Piperacillin-Tazobactam Against 3rd Generation cephalosporin resistant Enterobacterales.

Aggarwal Prabhav P, Saxena Sonal S, Amritha Anugula A, Kaim Manisha M

The rise of extended-spectrum β-lactamase (ESBL) and carbapenem-resistant Enterobacterales (CRE) has severely limited treatment options in India. Cefepime-enmetazobactam (FPE), a novel β-lactam/β-lactamase inhibitor combination approved by the US FDA in 2024, shows promise as a carbapenem-sparing agent. A total of 383 non-duplicate resistant isolates of Escherichia coli and Klebsiella pneumoniae subsp. pneumoniae. were studied (January 2023-December 2024) at a tertiary-care centre in New Delhi. Isolates were categorized as third generation cephalosporin resistant but carbapenem-susceptible (Group A, n=258) or carbapenem-resistant (Group B, n=125). Antimicrobial susceptibility was determined by CLSI disc diffusion, and synergy with aztreonam was evaluated. Among Group A isolates, FPE exhibited the highest activity-95.4% E. coli and 97.4% K. pneumoniae susceptibility-outperforming ceftazidime-avibactam (88.1% and 84.6%) and Piperacillin tazobactam (5.4% and 10.2%, respectively). In Group B (CRE), activity was significantly lower: FPE (13% E. coli, 14.3% K. pneumoniae), CZA (31.9% and 7.1%), and PT (0%). ESBL production was observed in 88% of Group A isolates, predominantly blaCTX-M (94%), while all CRE carried blaNDM and blaOXA-48 genes. FPE-aztreonam synergy was infrequent (≤4%). Cefepime-enmetazobactam demonstrated superior in vitro activity to CZA and Piperacillin Tazobactam against ESBL-producing but carbapenem-susceptible Enterobacterales, making it a potent carbapenem-sparing option.

PMID 42669540
Read full article →
PubMedKorean journal of medical education2026-08-30

A pharmacist-led, workplace-based educational intervention informed by behavioral science to influence antimicrobial prescribing in Japan.

Masuda Koji K, Gomi Harumi H, Tanuma Junko J, Hiramatsu Tamae T et al.

Changing antimicrobial prescribing behavior is a key challenge in antimicrobial stewardship (AMS). In postgraduate clinical education, knowledge-based teaching alone is often insufficient to achieve sustained behavior change, highlighting the need for workplace-based educational designs informed by behavioral science. We conducted a retrospective before-after study to evaluate a pharmacist-led educational intervention designed to influence prescribing behavior of piperacillin/tazobactam (TZP) in Japan. The educational component, consisting of a pharmacist-developed video and post-test, was completed once by physicians prior to implementation, whereas a structured prescription rationale requirement was applied at each TZP prescribing event. Prescribing behavior was assessed using days of therapy (DOT) and antibiotic use density (AUD) over 6 months before and after the intervention. Educational components were treated as process indicators of engagement rather than primary outcomes. All full-time physicians completed the instructional video and the post-test. Following the intervention, TZP use decreased by 22.3% in DOT, with consistent reductions observed in season-matched comparisons. Similar trends were observed for AUD. Workflow-embedded reflective prompts may be useful as a workplace-based educational strategy for influencing antimicrobial prescribing behavior.

PMID 42669608
Read full article →
PubMedClinical pharmacokinetics2026-08-29

Protein Binding Determination of Cefepime, Flucloxacillin, Meropenem, Piperacillin and Tazobactam by Ultrafiltration in Critically Ill Patients: The Choice of Device Matters.

Gregoire Matthieu M, Wallis Steven C SC, Williams Paul G PG, Won Hayoung H et al.

Therapeutic drug monitoring (TDM) and pharmacokinetic studies of beta-lactam antibiotics in critically ill patients aim to define optimal dosing and require accurate measurement of unbound drug concentrations. This study compared the performance of two ultrafiltration devices, Centrifree and Amicon, for measuring unbound concentrations of cefepime, meropenem, flucloxacillin, piperacillin and tazobactam. Non-specific binding (NSB) was specifically assessed in phosphate-buffered saline, and unbound concentrations were measured using a chromatographic method in both spiked plasma and plasma samples from critically ill patients, in order to compare the two ultrafiltration devices. Centrifree exhibited no significant NSB for any antibiotics (≤ 15%), while Amicon displayed significant NSB for meropenem (26-61%), flucloxacillin (18-58%) and piperacillin (15-72%), resulting in lower unbound concentrations in both patient and spiked plasma samples compared to Centrifree. Additionally, piperacillin, and to a lesser extent flucloxacillin, demonstrated concentration-dependent NSB with Amicon. The comparative mean ± standard deviation of unbound fractions in intensive care unit (ICU) patients were as follows: cefepime, 0.85 ± 0.12 (Centrifree) versus 0.90 ± 0.10 (Amicon); meropenem, 0.87 ± 0.07 (Centrifree) versus 0.77 ± 0.05 (Amicon); flucloxacillin, 0.25 ± 0.13 (Centrifree) versus 0.18 ± 0.13 (Amicon); piperacillin, 0.91 ± 0.07 (Centrifree) versus 0.67 ± 0.13 (Amicon); and tazobactam, 0.97 ± 0.08 (Centrifree) versus 0.95 ± 0.08 (Amicon). These findings underscore significant differences in results between ultrafiltration devices, depending on the drug, influenced by NSB. Such factors should be considered when developing methods for determining unbound concentrations of beta-lactam antibiotics.

PMID 42667589
Read full article →
PubMedCureus2026-08-29

Bordetella hinzii Antenatal Sepsis in a Pregnant Woman With Sickle Cell Disease and Intrauterine Fetal Demise: A rare and first case report from India.

Kulkarni Monika M, Shendre Pooja P, Taywade Vaishali V, Bhalavi Sangeeta S et al.

Bordetella hinzii is a rare, opportunistic Gram-negative bacterium traditionally associated with poultry but increasingly identified as a human pathogen in immunocompromised individuals. We report the first Indian case of B. hinzii causing antenatal sepsis in a 27-year-old pregnant woman with homozygous sickle cell anaemia and β-thalassemia minor, leading to intrauterine fetal demise at 24 weeks of gestation. The patient presented with breathlessness, edema, and absent fetal movements. Laboratory results showed severe anaemia, leucocytosis, and raised inflammatory markers. Blood cultures yielded B. hinzii, confirmed by the VITEK 2 system (bioMérieux, Marcy-l'Étoile, France). The isolate was susceptible to meropenem, piperacillin/tazobactam, cefepime, ceftazidime, and co-trimoxazole, but resistant to aminoglycosides and ceftriaxone. The patient improved with empirical therapy, though fetal loss had occurred. This case highlights the emerging clinical significance of B. hinzii in high-risk pregnancies and the need for advanced microbiological tools and antimicrobial therapy in managing rare opportunistic infections.

PMID 42666996
Read full article →
PubMedCureus2026-08-29

Phlegmonous Gastritis During Consolidation Therapy With High-Dose Cytarabine and FLT3 Inhibitor in FLT3-ITD-Mutated Acute Myeloid Leukemia.

Itamura Hidekazu H, Mihashi Tatsuya T, Hirano Yusuke Y, Kimura Shinya S

Phlegmonous gastritis (PG) is a rare disorder in which a bacterial infection arises in the gastric wall. We report a patient in his 60s with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)-mutated acute myeloid leukemia (AML) who developed PG during the consolidation therapy with high-dose cytarabine and the FLT3 inhibitor quizartinib. The patient developed fever, abdominal pain, hematemesis, and hypovolemic shock during neutropenia on day 17. Contrast-enhanced computed tomography (CT) showed edematous thickening of the gastric wall with perigastric fat stranding. Upper gastrointestinal endoscopy revealed diffuse edematous mucosa with erosions, and a gastric biopsy culture yielded Enterococcus faecium. Intravenous piperacillin/tazobactam, followed by ampicillin/sulbactam after clinical improvement, achieved complete clinical and radiologic resolution without surgical intervention. This case highlights the importance of early suspicion, prompt contrast-enhanced CT, and endoscopic biopsy with concurrent microbiological evaluation, followed by timely broad-spectrum antimicrobial therapy in immunocompromised patients with chemotherapy-induced neutropenia in the setting of hematological malignancy.

PMID 42666616
Read full article →
PubMedCureus2026-08-29

Disseminated Septic Emboli From Aortic Valve Infective Endocarditis in an Immunocompromised Patient: A Case Report.

Singh Mandeep M, Seeralan Sharmila S, Seeralan Mayuran M, Oladipo Olanrewaju O

Disseminated sepsis with septic embolic disease can present with a wide spectrum of clinical manifestations and may closely mimic metastatic malignancy or immune-related adverse events in oncology patients. We report the case of a 50-year-old woman with cervical squamous cell carcinoma receiving pembrolizumab and infliximab who presented with fever, progressive blistering skin lesions, non-pruritic rash, and new right-sided neurological deficits. Initial concerns included toxic epidermal necrolysis, immunotherapy-related toxicity, metastatic disease, and severe infection. Examination revealed haemorrhagic blisters involving the fingers and toes, truncal rash, and transient right-sided weakness. Blood investigations demonstrated markedly elevated inflammatory markers. Imaging showed a cavitating left lower lobe lung lesion with air-fluid level, bilateral pulmonary infiltrates, hepatic lesions, and ring-enhancing lesions within the left frontal and parietal lobes concerning for cerebral abscesses or metastases. MRI brain findings favoured cerebral abscesses with surrounding vasogenic oedema. Wound cultures from hand and foot lesions grew Streptococcus pyogenes (Group A Streptococcus). Multidisciplinary input from dermatology, oncology, respiratory medicine, microbiology, vascular surgery, gastroenterology, and neurosurgery guided management. The patient initially received empirical piperacillin-tazobactam and gentamicin for severe sepsis. Following multidisciplinary microbiology review, antimicrobial therapy was escalated to meropenem and teicoplanin to provide broad-spectrum coverage while the diagnostic evaluation was ongoing because of extensive cerebral, pulmonary, and soft tissue infection in an immunocompromised host. The patient demonstrated significant clinical and biochemical improvement, and pembrolizumab and infliximab were withheld. Neurosurgical intervention was not considered appropriate due to the extent of systemic disease and favourable response to medical management. This case highlights the diagnostic complexity of disseminated infection in immunocompromised oncology patients, particularly when septic emboli and cerebral abscesses mimic metastatic disease or immune-related adverse events. Early multidisciplinary assessment and prompt antimicrobial therapy were essential in achieving clinical stabilisation.

PMID 42666556
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about piperacillin